Labcorp Expands MRD Testing for Breast, Lung and Colon Cancer Recurrence Risk
MWN-AI** Summary
Labcorp, a leading laboratory services provider, has announced the expansion of its molecular residual disease (MRD) testing portfolio, which is designed to detect cancer recurrence risk earlier than traditional imaging methods. The updated offerings now monitor the recurrence risk for patients with stage I–III breast cancer, stage I–IIIA non-small cell lung cancer, and stage III colon cancer.
MRD testing utilizes a technique that identifies circulating tumor DNA (ctDNA) in the bloodstream, which can indicate a cancer's molecular recurrence months prior to traditional methods, signaling oncologists to adjust patient surveillance strategies proactively. Labcorp's Plasma Detect ID employs a whole exome sequence-guided approach specifically for patients with early-stage breast and lung cancer, while the Labcorp Plasma Detect Genome is a comprehensive whole-genome test aimed at stage III colon cancer patients. The sensitivity of these MRD tests, with a limit of detection down to 0.005%, enhances the potential for timely intervention and personalized patient care.
Despite advancements in treatment, cancer recurrence remains a significant risk, with approximately 35% of stage III colon cancer patients and 10% to 55% of patients across breast and lung cancer experiencing recurrence. The ability to monitor MRD can provide critical insights for oncologists and patients during a challenging period after curative treatment.
Moreover, Labcorp's commitment to advancing oncology diagnostics is evidenced by ongoing clinical studies underscoring the efficacy of their MRD tests, contributing to a growing body of research promoting personalized cancer care. This expansion underscores Labcorp's role in precision medicine, enhancing cancer care from diagnosis to monitoring and treatment selection, ultimately improving patient outcomes globally. For further information, interested parties can visit Labcorp’s oncology solutions page.
MWN-AI** Analysis
Labcorp's recent expansion of its molecular residual disease (MRD) testing portfolio represents a significant advancement in oncology diagnostics, enhancing their competitive positioning within the healthcare market. By offering early detection of cancer recurrence for breast, lung, and colon cancers, Labcorp is addressing a critical medical need, as current treatment outcomes show considerable recurrence rates—up to 55% for certain conditions.
Investors should note the potential impact of this development on Labcorp’s revenue streams. The integration of advanced MRD testing is likely to attract additional partnerships with healthcare providers and biopharma companies, thereby increasing its market reach. The personalized nature of MRD testing allows oncologists to tailor patient care more effectively, thus positioning Labcorp as a leader in precision medicine.
Furthermore, both the Labcorp Plasma Detect ID and Genome tests utilize sophisticated genomic profiling, which appeals to a growing market segment increasingly focused on personalized healthcare solutions. The ability to detect circulating tumor DNA (ctDNA) at incredibly low thresholds is a game-changer, providing clinicians with actionable insights long before traditional imaging methods yield results.
From a financial perspective, investors should consider Labcorp’s established base of nearly 70,000 employees and their extensive global operational footprint across approximately 100 countries. Given the rise in demand for innovative diagnostic services and ongoing collaborations within the pharmaceutical sector, Labcorp appears well-positioned for future growth.
However, potential investors should remain vigilant about market competition and regulatory challenges within the healthcare ecosystem. As advancements in technology continue to emerge, Labcorp’s ability to maintain a leadership position in the oncology space will hinge on its ongoing innovation, research credibility, and strategic partnerships. Overall, Labcorp appears to present a compelling investment opportunity, particularly as the demand for precise and early cancer detection rises.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
- Molecular residual disease (MRD) testing detects cancer recurrence months before traditional imaging
- Labcorp MRD tests now monitor recurrence risk across stage I–III breast cancer, stage I–IIIA non-small cell lung cancer and stage III colon cancer
BURLINGTON, N.C., Jan. 13, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the continued expansion of its molecular residual disease (MRD)i portfolio designed to help clinicians detect cancer recurrence earlier than traditional imaging. The expanded offerings include Labcorp Plasma Detect ID, a whole exome sequence-guided, personalized panel for patients with stage I–III breast cancer or stage I–IIIA non-small cell lung cancer, and the nationwide availability of Labcorp Plasma Detect Genome, a whole-genome MRD test for stage III colon cancer.
Despite advancements in treatment, cancer recurrence rates remain a significant concern for patients and clinicians. Approximately 35% of stage III colon cancer patients will experience recurrence after treatment, along with 10% to 40% of patients with stage I-III breast cancer, and 10% to 55% of patients with stage I–III non-small cell lung cancer.
MRD testing helps clinicians track a patient's risk of cancer recurrence by detecting small traces of circulating tumor DNA (ctDNA) in a patient's bloodstream following treatment. This can signal molecular recurrence months before clinical relapse appears on traditional imaging or causes symptoms. Both Labcorp Plasma Detect ID and Labcorp Plasma Detect Genome MRD tests can detect ctDNA down to a limit of detection (LOD95) of 0.005%. Earlier detection allows oncologists to tailor surveillance strategies and helps inform next steps, offering patients greater clarity during a critical period of uncertainty.
"For patients who have completed cancer treatment with curative intent, ongoing monitoring is essential to understand their risk of recurrence," said Shakti Ramkissoon, M.D., Ph.D., vice president, medical lead for oncology at Labcorp. "By expanding the Labcorp Plasma Detect portfolio, we're giving clinicians advanced tools to track molecular residual disease and detect recurrence risk earlier, supporting more personalized and proactive care, while increasing patient access to non-invasive testing options."
Labcorp has several ongoing and completed clinical studies that highlight the clinical utility of Labcorp Plasma Detect to track early disease progression, predict long-term outcomes, and identify residual cancer. Two peer-reviewed publications recently featured clinical studies of Labcorp Plasma Detect that focus on the test's utility in patients diagnosed with diffuse pleural mesothelioma and head and neck cancer, adding to a growing body of research that supports MRD testing as a critical component of personalized cancer care. In addition, data were presented at the recent AMP 2025 Annual Meeting outlining the continued development of Labcorp Plasma Detect Genome MRD.
The expanded Labcorp Plasma Detect portfolio builds on Labcorp's leadership in oncology diagnostics, supporting cancer care from screening and risk assessment, through diagnosis and prognosis, therapy selection and monitoring and surveillance. Through a full spectrum of clinical and oncology tests, including liquid biopsy, tissue-based comprehensive genomic profiling, and companion diagnostics, Labcorp partners with oncologists, health systems and biopharma companies to drive precision medicine, improving outcomes and expanding access for patients globally.
For more information about Labcorp's Oncology solutions, contact us at https://oncology.labcorp.com/contact-us
About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 70,000 employees serve clients in approximately 100 countries, provided support for more than 75% of the new drugs and therapeutic products approved in 2024 by the FDA, and perform more than 700 million tests annually for patients around the world. Learn more about us at www.labcorp.com.
i The term MRD is often used interchangeably between molecular residual disease and minimal residual disease. Labcorp Plasma Detect detects molecular residual disease, which is defined as the subclinical presence of a cancer-associated biomarker indicating a high risk of recurrence, which cannot be detected by standard imaging techniques. MRD terminology is in accordance with the BLOODPAC Consortium.
SOURCE Labcorp
FAQ**
How does the expansion of Labcorp's MRD testing capabilities enhance the ability of clinicians to manage the recurrence risk in patients treated for breast, lung, and colon cancer, particularly for Laboratory Corporation of America Holdings LH?
What clinical studies support the efficacy of Labcorp's Plasma Detect portfolio in detecting cancer recurrence earlier than traditional imaging, and how does this impact patient outcomes for Laboratory Corporation of America Holdings LH?
How does Labcorp's MRD testing align with current trends in personalized medicine, and what role does Laboratory Corporation of America Holdings LH see for these advancements in the future of oncology diagnostics?
What strategies is Labcorp implementing to increase patient access to non-invasive MRD testing options, and how does this support the mission of Laboratory Corporation of America Holdings LH to improve health outcomes globally?
**MWN-AI FAQ is based on asking OpenAI questions about Laboratory Corporation of America Holdings (NYSE: LH).
NASDAQ: LH
LH Trading
-1.28% G/L:
$265.89 Last:
149,640 Volume:
$265.60 Open:
